Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.39 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15806349 | 0.89 | SMURF2 (0.42) | SMURF2SMURF1PDE10ASLC6A2SLC6A3 | |
| SCHEMBL28308049 | 0.79 | SMURF2 (0.38) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL249140 | 0.79 | CD44 (0.35) | SMURF2SMURF1PDE10ASLC6A2SLC6A3 | |
| SCHEMBL11981506 | 0.78 | SLC6A2 (0.35) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14535838 | 0.76 | SMURF2 (0.39) | SMURF2SMURF1PDE10ASLC6A2SLC6A3 | |
| SCHEMBL24986844 | 0.75 | KDM4E (0.35) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL30164168 | 0.75 | KDM4E (0.35) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16978495 | 0.74 | ESR2 (0.47) | SMURF2SMURF1SLC6A3KCNH2HTR2A | |
| SCHEMBL879247 | 0.74 | SLC6A2 (0.57) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL17877599 | 0.74 | HTR2A (0.33) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8481581-B2 | S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481581-B2 | S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2609917-A1 | Triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2402011-B1 | S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-7683087-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-2135608-A1 | S-triazolyl alpha -mercaptoacetanilides as inhibitors of HIV reverse transcriptase | Ardea Biosciences, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20080319201-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC., A CALIFORNIA CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080319201-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC., A CALIFORNIA CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | SMURF2 786/4885SMURF1 1511/4885PDE10A 4443/4885 |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | SMURF2 786/4885SMURF1 1511/4885PDE10A 4443/4885 |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, ME2 | SMURF2 530/4885SMURF1 1704/4885PDE10A 4162/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | SMURF2 786/4885SMURF1 1511/4885PDE10A 4443/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | SMURF2 1037/4885SMURF1 2020/4885PDE10A 4591/4885 |
| US-20080319201-A1 | N[S(4-ARYL-TRIAZOL-3-YL)alpha-MERCAPTOACETYL] -P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS | NQO2, NAT1, QPCT | SMURF2 3301/4885SMURF1 3037/4885PDE10A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.